Brukinsa Tablet, Film Coated
Product Images NDC 72579-122

5 FDA label images from Beone Medicines Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Brukinsa (NDC 72579-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Beone Medicines Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Brukinsa 01)

Chemical Structure (Brukinsa 01)
Chemical structure diagram of zanubrutinib, the active ingredient in BRUKINSA tablets. The structure features multiple rings, including aromatic and nitrogen-containing heterocycles, as well as oxygen and amine functional groups.*
FDA Label Image

Figure 1 (Brukinsa 02)

Figure 1 (Brukinsa 02)
Packaging label for Brukinsa zanubrutinib capsules, 80 mg strength. The label indicates the product is supplied in a package containing 120 capsules. It includes storage instructions and a warning to keep out of reach of children. The labeler is BeiGene USA, Inc., San Mateo, CA, USA. The label also advises not to open, break, or chew the capsules.*
FDA Label Image

Figure 2 (Brukinsa 03)

Figure 2 (Brukinsa 03)
A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months from randomization for zanubrutinib and ibrutinib treatment groups. The chart includes lines for zanubrutinib and ibrutinib, with censored data points marked. Below the x-axis is a table indicating the number of subjects at risk at various time intervals for each treatment group.*
FDA Label Image

Principal Display Panel (80 mg Capsule Carton)

Principal Display Panel (80 mg Capsule Carton)
Packaging label for Brukinsa zanubrutinib capsules, 80 mg strength. The label shows it is an oral capsule formulation provided by BeOne Medicines USA, Inc. The package includes 120 capsules. Instructions indicate to swallow capsules whole and not to open, break, or chew them. Storage conditions and a warning to keep out of reach of children are also included.*
FDA Label Image

Principal Display Panel (160 mg Tablet Carton)

Principal Display Panel (160 mg Tablet Carton)
Label for Brukinsa 160 mg film-coated tablets, containing zanubrutinib, for oral use. The carton shows the BeOne Medicines USA, Inc. labeler and manufacturing by Catalent Pharma Solutions, LLC. The packaging highlights 60 tablets per carton with storage instructions and warnings. The NDC number 72579-122-01 is visible, with a barcode present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.